UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/722,155	11/25/2003	Theodore R. Sana	10030511-1	8586
	7590 07/17/200 CHNOLOGIES , INC.	EXAMINER		
Legal Departme	ent, DL429	BABIC, CHRISTOPHER M		
Intellectual Property Administration P.O. Box 7599			ART UNIT	PAPER NUMBER
Loveland, CO 8	80537-0599	1637		
			MAIL DATE	DELIVERY MODE
			07/17/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/722,155	SANA ET AL.		
Examiner	Art Unit		
CHRISTOPHER M. BABIC	1637		

	CHINETOT HEIL W. BABIC	1007
The MAILING DATE of this communication a	appears on the cover sheet with the	correspondence address
THE REPLY FILED <u>19 May 2008</u> FAILS TO PLACE THIS .	APPLICATION IN CONDITION FOR A	LLOWANCE.
1. The reply was filed after a final rejection, but prior to capplication, applicant must timely file one of the follow application in condition for allowance; (2) a Notice of for Continued Examination (RCE) in compliance with periods:	ving replies: (1) an amendment, affidav Appeal (with appeal fee) in compliance 37 CFR 1.114. The reply must be filed	it, or other evidence, which places the with 37 CFR 41.31; or (3) a Request
a) The period for reply expiresmonths from the m		
b) The period for reply expires on: (1) the mailing date of to no event, however, will the statutory period for reply expected the Examiner Note: If box 1 is checked, check either box (a)	pire later than SIX MONTHS from the mailin a) or (b). ONLY CHECK BOX (b) WHEN THE	g date of the final rejection.
MONTHS OF THE FINAL REJECTION. See MPEP 700 Extensions of time may be obtained under 37 CFR 1.136(a). The have been filed is the date for purposes of determining the period under 37 CFR 1.17(a) is calculated from: (1) the expiration date of set forth in (b) above, if checked. Any reply received by the Office may reduce any earned patent term adjustment. See 37 CFR 1.70 NOTICE OF APPEAL	date on which the petition under 37 CFR 1.1 of extension and the corresponding amount the shortened statutory period for reply orig later than three months after the mailing da	of the fee. The appropriate extension fee inally set in the final Office action; or (2) as
2. The Notice of Appeal was filed on A brief in c	compliance with 37 CFR 41.37 must be	filed within two months of the date of
filing the Notice of Appeal (37 CFR 41.37(a)), or any Notice of Appeal has been filed, any reply must be file AMENDMENTS	extension thereof (37 CFR 41.37(e)), to	avoid dismissal of the appeal. Since a
 The proposed amendment(s) filed after a final reject (a) They raise new issues that would require further (b) They raise the issue of new matter (see NOTE) 	er consideration and/or search (see NO	
(c) ☐ They are not deemed to place the application in appeal; and/or (d) ☐ They present additional claims without cancelin	n better form for appeal by materially re	
NOTE: (See 37 CFR 1.116 and 41.33		ected claims.
4. The amendments are not in compliance with 37 CFR		empliant Amendment (PTOL-324).
5. Applicant's reply has overcome the following rejection		,
 Newly proposed or amended claim(s) would be non-allowable claim(s). 	pe allowable if submitted in a separate,	
7. For purposes of appeal, the proposed amendment(s) how the new or amended claims would be rejected is The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: Claim(s) withdrawn from consideration:		ll be entered and an explanation of
AFFIDAVIT OR OTHER EVIDENCE		
 The affidavit or other evidence filed after a final action because applicant failed to provide a showing of good was not earlier presented. See 37 CFR 1.116(e). 		
 The affidavit or other evidence filed after the date of f entered because the affidavit or other evidence failed showing a good and sufficient reasons why it is neces 	l to overcome <u>all</u> rejections under appea	al and/or appellant fails to provide a
10. ☐ The affidavit or other evidence is entered. An explar REQUEST FOR RECONSIDERATION/OTHER	nation of the status of the claims after e	ntry is below or attached.
The request for reconsideration has been considere See Continuation Sheet.	d but does NOT place the application in	n condition for allowance because:
12. ☐ Note the attached Information <i>Disclosure Statement</i>13. ☐ Other:	f(s). (PTO/SB/08) Paper No(s)	
/GARY BENZION/		
Supervisory Patent Examiner, Art Unit 1637		

Continuation of 11. does NOT place the application in condition for allowance because:

As an initial matter, it is noted that the examiner of record has changed from Young Kim, Art Unit 1637 to Christopher Babic, Art Unit 1637.

Applicant's arguments filed May 19, 2008 have been fully considered but are not persuasive. The examiner has reviewed the FINAL Office Action dated March 17, 2008 and agrees with Examiner Kim that the phrase "at least", broadly interpreted, means that the so called, "two or more different biopolymer subunit precursors" need not be deposited to a feature location at once, but can be applied in more than single round, such as second round, third round, etc (see FINAL Office Action 3/17/2008 pg. 5).

First, the section of specification highlighted by Applicant (see pg. 7 of response) is in no way a limiting definition of the term "mixture" or the phrase "at least." Second, the section actually supports the Office's interpretation because the 4th nucleotide G, and the subsequent different nucleotides C, A, and T, i.e. the 5th nucleotides, are added in successive "rounds" of extension. The cited prior art clearly discloses successive addition of different nucleotide subunits in the formation of a polynucleotide.

With specific regard to the arguments regarding Cheteverin, Applicant is reminded that one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See In re Keller, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); In re Merck & Co., 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986). Cheteverin provides a teaching of degenerate oligonucleotide in the same feature location of an array. Thus, combined with the prior art, i.e. sequential synthesis, synthesizing a plurality of oligonucleotides in one area, wherein one position is degenerate will result in the dispensing of different nucleotides in the same area (such as A, T, G, and C) in a single pass of nucleotide additions, rendering the instant invention as claimed prima facie obvious over the cited references.